论文部分内容阅读
目的:评价雷贝拉唑与溃愈颗粒联用治疗Hp阳性十二指肠球部溃疡患者的临床疗效。方法:选取2011年2月—2014年6月间收治的Hp阳性十二指肠球部溃疡患者140例作为研究对象,采用随机数字表法将其分为治疗组和对照组,各70例;治疗组患者给予雷贝拉唑与溃愈颗粒联用治疗,对照组患者给予雷贝拉唑治疗,评价两组患者临床治疗的总有效率、Hp根除率、溃疡复发率及Hp再感染率。结果:治疗组患者临床治疗的总有效率为95.71%,稍高于对照组为92.86%(P>0.05);治疗组Hp根除率为92.86%,略同对照组为91.43%(P>0.05);随访患者6月,治疗组溃疡复发率及Hp再感染率分别为1.43%和4.29%,均显著优于对照组为11.43%和15.71%(P<0.05)。结论:雷贝拉唑与溃愈颗粒联用治疗Hp阳性十二指肠球部溃疡患者,其疗效较确切,可明显改善临床症状,减少溃疡复发和Hp再感染率。
Objective: To evaluate the clinical efficacy of rabeprazole in combination with ulcerative granules in the treatment of Hp-positive duodenal ulcer patients. Methods: A total of 140 Hp - positive duodenal ulcer patients admitted between February 2011 and June 2014 were selected as study subjects. The patients were divided into treatment group and control group with 70 cases in each group by random number table. Patients in the treatment group were treated with rabeprazole in combination with Kuyu Granule, while those in the control group were given rabeprazole. The total effective rate, Hp eradication rate, ulcer recurrence rate and Hp re-infection rate in both groups were evaluated. Results: The total effective rate of clinical treatment in the treatment group was 95.71%, slightly higher than that in the control group (92.86%, P> 0.05). The eradication rate of Hp in the treatment group was 92.86%, slightly higher than that in the control group (91.43% ; The follow-up of patients in June, the treatment group ulcer recurrence rate and Hp re-infection rates were 1.43% and 4.29%, were significantly better than the control group was 11.43% and 15.71% (P <0.05). Conclusion: Rabeprazole combined with ulcerative granules in the treatment of Hp-positive duodenal ulcer in patients with exact effect, can significantly improve clinical symptoms and reduce the recurrence of ulcers and Hp re-infection rate.